This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up
by Zacks Equity Research
Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.
3 Reasons Growth Investors Will Love HealthEquity (HQY)
by Zacks Equity Research
HealthEquity (HQY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls
by Zacks Equity Research
ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
by Zacks Equity Research
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Thermo Fisher Q3 Earnings Top Estimates, Revenues Miss, Stock Dips
by Zacks Equity Research
In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
by Zacks Equity Research
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
HealthEquity, Inc. (HQY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights Elevance Health, Doximity and HealthEquity
by Zacks Equity Research
Elevance Health, Doximity and HealthEquity are part of the Zacks Industry Outlook article.
3 Medical Services Stocks to Buy to Navigate Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
HealthEquity Gains 28.3% YTD: What's Driving the Stock?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action
by Zacks Equity Research
Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy HealthEquity (HQY) Now
by Zacks Equity Research
HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.
Alignment HealthCare Partners With Intermountain Health in Nevada
by Zacks Equity Research
ALHC partners with Intermountain Health to enhance access to high-quality care for Medicare members in Clark and Washoe counties, starting Jan 2025.
Why Is HealthEquity (HQY) Down 4.3% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is HealthEquity Stock a Buy Now Amid Strength in HSAs?
by Zacks Equity Research
HQY's strong quarterly results and solid top-line growth raise optimism about the stock.
Looking for a Growth Stock? 3 Reasons Why HealthEquity (HQY) is a Solid Choice
by Zacks Equity Research
HealthEquity (HQY) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts Think HealthEquity (HQY) Could Surge 32.88%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for HealthEquity (HQY) points to a 32.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.